Whalesbook
Okay, toh suno, Indegene ne Q4 FY26 mein kya dhamaka kiya hai! Revenue toh unka 32.8% uddan bhar kar ₹1,003.4 Crore ho gaya. Full year ka bhi dekho toh 23.6% badh kar ₹3,510.5 Crore pahunch gaya. Ye toh badhiya news hai na?
Par yahan ek twist hai! Jab profit ki baat aayi, toh woh seedha 32.2% gir kar ₹79.7 Crore reh gaya. Margins bhi tight ho gaye, EBITDA margin 19.5% se 16.3% par aa gaya. Iska reason kya hai? Company ne jo naye acquisitions kiye hain na, unki wajah se depreciation aur amortization ka kharcha 57.6% badh gaya. Aur kuch one-time costs bhi the, jaise ki ₹20.3 Crore ka loss Q4 mein.
Is sab wajah se, 29 April 2026 ko stock 0.41% gir kar band hua. Log revenue se zyada profit par focus kar rahe hain.
Ab ye company health-tech aur IT services sector mein hai, jahan opportunities toh bahut hain. Indian IT sector mein FY2026 mein around 2-3% revenue growth ki ummeed hai, par health-tech toh rocket banne wala hai, 41.8% CAGR se grow karega AI ke saath. Indegene ka P/E ratio lagbhag 30-31.7x hai, jo LTTS aur Happiest Minds ke aas paas hai. Tata Elxsi toh aur upar hai. Par Dr. Lal Pathlabs jaise healthcare providers (jo 29.3x par hain) ke comparison mein, Indegene ka valuation thoda premium lag raha hai, aur ye premium justify karne ke liye profit ka stable rehna zaroori hai.
Inki strategy hai acquisitions se grow karne ki, jaise BioPharm aur WARN & Co. Isse intangible assets aur depreciation badh raha hai. CFO Suhas Prabhu ne bhi bola ki M&A ke one-time costs ne profit kam kiya. Lekin profit margin ka consistently girna ek alag concern hai. Aur bhai, inke upar debt bhi bahut hai! Debt-to-equity ratio 7.62 hai. Agar profit revenue ke saath nahi badha, toh ye high debt ek bada risk ban sakta hai.
Waise toh analysts abhi bhi positive hain. Mostly 'Buy' rating de rahe hain, aur average target price ₹568.57 ke aas paas hai. Jaise ICICI Securities ne 'BUY' rating maintain ki hai, AI strategy aur sector demand ko dekh kar. Par ye positive outlook thoda clash kar raha hai aaj ke results se, jahan profit gir raha hai aur margins tight hain. Analyst ne kuch fair value estimates bhi adjust kiye hain.
Management toh optimistic hai. Health-tech sector mein FY26 se FY28 tak 5-8% CAGR dekh rahe hain aur biotech deal pipeline bhi strong lag rahi hai. ICICI Securities ne March 2027 tak target ₹620 diya hai, jo 24x forward P/E par based hai. Ye current P/E se kam hai, matlab future mein earnings growth achhi honi chahiye valuation ko justify karne ke liye. Ab dekhte hain ki ye company apne revenue growth ko sustainable profit mein convert kar pati hai ya nahi, khaas kar jab integration costs aur operational efficiency ke challenges hain. AI aur acquisitions ko properly manage karna hi inka key hoga.